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ABSTRACT
Introduction Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 
(SARS-CoV-2), has quickly spread around the world.
Areas covered This review will discuss the available immunologic and clinical evidence to support the 
benefit of the influenza, pneumococcal, and tuberculosis vaccines in the context of COVID-19 as well as 
to provide an overview on the COVID-19-specific vaccines that are in the development pipeline. In 
addition, implications for vaccination strategies from a public health perspective will be discussed.
Expert opinion Some vaccines are being considered for their potentially beneficial role in preventing 
or improving the prognosis of COVID-19: influenza, pneumococcal and tuberculosis vaccines. These 
vaccines may have either direct effect on COVID-19 via different types of immune responses or indirect 
effects by reducing the burden of viral and bacterial respiratory diseases on individual patients and 
national healthcare system and by facilitating differential diagnoses with other viral/bacterial respiratory 
disease. On the other hand, a large number of candidate vaccines against SARS-CoV-2 are currently in 
the pipeline and undergoing phase I, II, and III clinical studies. As SARS-CoV-2 vaccines are expected to 
be marketed through accelerated regulatory pathways, vaccinovigilance as well as planning of a 
successful vaccination campaign will play a major role in protecting public health.
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Coronavirus disease (COVID-19) is an infectious disease first 
reported in the city of Wuhan (China) which quickly spread to 
the rest of the world [1]. COVID-19 is caused by the newly 
discovered severe acute respiratory syndrome coronavirus 
(SARS-CoV-2). Since the outbreak, more than 16.4 million 
cases of COVID-19 have been worldwide confirmed, with 
653,862 deaths as of July 28th, 2020 [2]. The current lack of 
effective interventions to prevent or treat COVID-19 infection 
has turned clinicians’ attention to repurpose already available 
treatments for off-label use of COVID-19, while waiting for the 
results of the many ongoing clinical studies of specific SARS- 
CoV-2 vaccines [3]. In addition, there is growing interest in 
some of the existing vaccines which prevent viral or bacterial 
respiratory diseases, specifically the influenza vaccine, the 
pneumococcal vaccine and tuberculosis Bacillus Calmette- 
Guérin (BCG) vaccine, as these may hypothetically play a role 
in COVID-19 prevention. This interest is triggered by evidence 
that live attenuated vaccines, such as the BCG vaccine, appear 
to protect against other seemingly unrelated pathogens [4]. In 
addition, the role of other vaccines concerning more common 
respiratory diseases, such as influenza and Streptococcus pneu-
moniae- respiratory infections, also came under scrutiny since 
contracting these diseases may make persons more vulnerable 
to COVID-19. It has therefore been suggested that the influ-
enza, pneumococcal, and the BCG vaccines may have direct 
benefits concerning COVID-19 infection [5,6], but the under-
lying pre-clinical and clinical evidence has not been yet 
explored in detail. They may also have indirect benefits, such 
as reducing the burden of preventable super-infections 
among COVID-19 patients as well as facilitating differential 
diagnosis in patients with symptoms related to respiratory 
infections. The increased uptake of these three vaccines may 
have implications on vaccination campaigns addressing frail 
and elderly populations in the coming months [7]. On the 
other hand, a large number of candidate vaccines against 
SARS-CoV-2 are currently in the pipeline, undergoing phase 
1, 2, and even 3 studies, as reported in clinicaltrials.gov, and 
emerging findings has been starting to be published [8,9]. As 
SARS-CoV-2 vaccines are expected to be marketed through 
accelerated regulatory pathways [10], vaccinovigilance as well 
as the planning of a successful vaccination campaign will play 
a major role in protecting public health. The aim of this review 
is to discuss the available immunologic and clinical evidence 
to support the benefit of the influenza, pneumococcal and 
tuberculosis vaccines to prevent or improve the prognosis of 
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COVID-19; in addition, it provides an overview of the state of 
the art about the COVID-19 vaccines that are currently in the 
development pipeline. Finally, from a public health perspec-
tive, implications for vaccination strategies to be adopted in 
the next months will be discussed.
2. Immunologic mechanisms behind the usefulness 
of existing vaccines in COVID-19 infection
A vaccine, by definition, is a biological preparation that pro-
vides acquired immunity to a particular infectious disease [11]. 
This occurs by activating lymphocytes bearing receptors spe-
cific for the given disease-causing microorganism, its toxins or 
one of its surface proteins [12]. Because of this specificity, it 
can appear paradoxical that such a specific preparation might 
also protect against other microorganisms. Nevertheless, inter-
ference between the influenza vaccine and infections by other 
respiratory viruses has been reported [13,14]. More recently, 
a possible link between the BCG vaccine and increased immu-
nity against COVID-19 infection has also been proposed [15– 
17]. The precise mechanism behind a non-SARS-CoV-2 vaccine 
evoking an increased or decreased response against SARS-CoV 
-2, a microorganism that is not related to any of the currently 
available vaccines, is still to be fully elucidated. To shed some 
light on the possible mechanisms of interference, at least 
three distinct mechanisms can be in general hypothesized: 
antigen mimicry, by-stander activation and trained immunity.
Antigen mimicry can occur when some antigens are shared 
between microorganisms or when there is sufficient similarity 
between molecules belonging to two different pathogens, 
thus giving rise to immunological mimicry with resulting acti-
vation and clonal expansion of lymphocytes specific to both 
vaccine antigens and other pathogens [18]. However, it is 
unlikely that this would occur between unrelated pathogens, 
because antigen mimicry is contingent on the degree of 
molecular similarity between different antigens [19]. For exam-
ple, it is unlikely that a vaccine developed to protect against 
a specific bacterial infection would protect against viral infec-
tions not displaying sufficient structural similarity. By-stander 
activation occurs when there is antigen-independent activa-
tion of by-stander lymphocytes during human immune 
response [20]. This is believed to play an important role in 
several immunological phenomena, such as T and B cell mem-
ory [21,22] This putative mechanism of interference would 
likely rely on the magnitude of the immune response after 
vaccination, on vaccine adjuvant properties and, on the pre-
sence of an initial immune response against the pathogen, in 
this case SARS-CoV-2 [23]. Trained immunity is perhaps the 
most widely investigated mechanism among the possible 
mechanisms of vaccine interference [24]. It concerns an epi-
genetic reprogramming of cells of the immune system, mainly 
innate cells, after vaccination [25,26]. Such an event has been 
clearly described for the BCG vaccine in both murine and 
human studies, and has been found to promote the elimina-
tion of various non-mycobacterium infection including staphy-
lococci, candidiasis, yellow fever, influenza [27]. The BCG 
vaccine led not only to a four- to seven-fold increase in IFN-γ 
production, but also to a two-fold enhanced release of mono-
cyte-derived cytokines, such as TNF and IL-1β, in response to 
unrelated bacterial and fungal pathogens [27]. The increased 
presence of these cytokines in respiratory mucosal tissues, 
where monocyte-derived sentinel cells such as dendritic cells 
are present [28], can improve innate immune barrier functions, 
thus possibly protecting against viral invasion. This increased 
activity of circulating monocytes remained for up to 3 months 
after the BCG vaccine administration and co-occurred with 
a higher expression of the activation markers CD11b and Toll- 
like receptor 4. Such training effects were found to be 
mediated through the NOD2 receptor and increased levels of 
histone 3 lysine 4 trimethylation. The limited duration of this 
innate immunity activation following BCG administration 
might also justify, at least in part, the negative results 
obtained by a retrospective study analyzing childhood BCG 
vaccine and current COVID-19 in adults [29]. However, it 
should be emphasized that a direct effect of the existing 
vaccines to prevent COVID-19 is not yet fully corroborated 
by clinical data. It is likely that the main benefit of administer-
ing the BCG, pneumococcal and influenza vaccine is to pre-
vent these diseases, and as a result, protect the respiratory 
airways, maintaining the mucosal respiratory tract healthy and 
effective. Although the lungs have been traditionally regarded 
as passive gas exchange organs, it is becoming evident that 
airway epithelial cells play a critical defense role in containing 
microorganism invasion [30]. They do not only act as 
a physical barrier, modulating their cell-to-cell junctions and 
maintaining a suitable muco-ciliar activity, but they also 
defend against pathogen invasion by signaling to leukocytes 
and by directly producing anti-microbial substances [31]. The 
protective arsenal of the respiratory mucosa includes a wide 
array of receptors able to sense invading pathogens [31]. As 
a whole, all these functions of the upper airway epithelium, 
which is the first point of contact for inhaled foreign organ-
isms such as SARS-Cov-2, are complex responses that are part 
of the early innate immunity. Any inflammatory damage to the 
respiratory mucosal tissue, caused by common pathogens, 
such as Streptococcus pneumoniae and the influenza virus, 
could impair these protective defense mechanisms, paving 
the way for the invasion of other respiratory pathogens, 
including SARS-CoV-2, thus emphasizing the potential useful-
ness of vaccines to prevent common respiratory infections in 
the control of the current pandemic.
3. Clinical evidence of direct/indirect effects of 
existing vaccines on COVID-19
A multi-level approach was used to identify evidence about 
vaccines preventing or improving prognosis of COVID-19. First, 
a search in MEDLINE using a specific search query was carried 
out (see Appendix Box 1). Only articles reporting original 
research findings on the association between the three vac-
cines of interest and clinical outcomes (SARS-CoV-2 infection 
and COVID-19 relate hospitalization, length of hospital stay or 
mortality, etc.), published from 2019 onward and written in 
English were selected for inclusion. Secondly, clinicaltrials.gov 
was also searched for clinical trials which are being planned, 
conducted or already finalized, concerning the three vaccines 
of interest in the COVID-19 prevention as well as trials con-
cerning specific COVID-19 vaccines. Thirdly, the EU PAS 
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Register, a register of post-authorization studies, set up by the 
European Medicine Agency, was queried to identify observa-
tional studies being conducted for the three vaccines of inter-
est in the context of COVID-19. All these study repositories 
were searched on the 22nd July concerning the role of the 
influenza, pneumococcal and BCG vaccine in 2020.
3.1. Influenza vaccine
There are two types of influenza vaccines available to date: the 
inactivated influenza vaccine (IIV) and live attenuated influ-
enza vaccines (LAIV). The IIV and LAIV are also referred to as 
trivalent vaccines because they protect against three different 
strains of seasonal flu virus, influenza A (H3N2), pandemic 
A (H1N1), and one of influenza B lineage virus [32]. 
Quadrivalent vaccines that protect against 4 strains of viruses, 
including both influenza B lineage viruses, have also been 
recently made available in some countries [33]. The influenza 
vaccine acts by inducing a humoral response to the influenza 
virus surface antigens [34] or inactivated split virions [35], 
contained in the vaccine, as antibodies are produced against 
haemagglutinins, thus neutralizing influenza viruses [36]. The 
live attenuated influenza vaccine, available as a nasal spray 
[37], elicits both a cellular and a humoral response [38].
A total of 167 papers were identified in MEDLINE, of which 
three original articles were considered to be of interest (Table 
1). A letter to the editor concerning an observational research 
study conducted in Italy showed a modest negative correla-
tion between the proportion of influenza vaccinated people 
>65 years and the number of deaths from COVID-19 (r: −0.59; 
p value: 0.005) [39]. Another observational study in the US, 
showed that a 10% increase in vaccine uptake may corre-
spond to approximately a 30% reduction in mortality among 
COVID-19 patients, thus suggesting a potential protective role 
of the influenza vaccine on COVID-19 in this population [40]. 
However, these studies are limited by the fact that they used 
aggregated, rather than patient-level data, and did not report 
the number of patients included. A prospective, registry-based 
observational study was published which aimed to develop 
COVID-19 risk prediction models [5]. This study enrolled 
11,672 persons who visited Cleveland Clinic, of whom 7% 
were SARS-CoV-2 positive persons. The authors concluded 
that the influenza vaccine may be associated with a lower 
risk of contracting COVID-19.
The search in clinicaltrials.gov yielded no clinical trials and 
only one observational study exploring the association of the 
influenza vaccine and COVID-19 (NCT04367883) through the 
recruitment of 2,574 patients admitted to the Terrassa 
Hospital in Barcelona and expected to be completed by 
August 2023. The aim of this observational study is to inves-
tigate if the patients admitted to hospital who had previously 
received the influenza vaccine had better clinical outcomes 
(shorter hospital stay and/or shorter intensive care unit stay) 
compared to persons who did not receive the vaccine. There 
are currently no registered studies in the EU PAS Register 
which are investigating the use, safety or effectiveness of the 
influenza vaccine in the context of the COVID-19 pandemic.
Although there is little clinical evidence concerning poten-
tial direct benefits or harms for COVID-19 treatment or pre-
vention, a recent study has shown that influenza A virus can 
facilitate SARS-CoV-2 entry into lung epithelial cells and wor-
sen clinical outcomes of COVID-19 infection [41]. Researchers 
have isolated SARS-CoV-2 from COVID-19 positive patients and 
compared its replication and viral tropism with SARS-CoV, 
MERS-CoV, H1N1, and H5N1 in ex vivo cultures of human 
bronchial and lung tissue [41]. They observed an overexpres-
sion of angiotensin-converting enzyme 2 (ACE2) receptors in 
alveolar epithelial cells following an influenza-like infection. 
This is important as ACE2 receptors facilitate the entry of 
SARS-CoV-2 into cells [41]. As such, a protective effect of 
influenza vaccine on COVID-19 can be speculated. In addition, 
the role of the influenza vaccine in reducing the burden of 
excess deaths due to COVID-19 should be emphasized. 
Indeed, it has been estimated that the influenza vaccine, by 
way of preventing influenza super-infection among COVID-19 
patients, could reduce up to 36% of all preventable deaths 
among COVID-19 patients [42]. The indirect benefits of the 
influenza vaccine are therefore likely to be significant.
The WHO, the Australian Department of Health and the 
Italian Drug Agency suggest that the administration of the 
seasonal influenza vaccine may be useful to prevent influenza 
at a time where many persons are also at risk of COVID-19 [43– 
45]. Indeed, in a study conducted among 191 persons with 
COVID-19 from two hospitals in Wuhan, 15% of patients devel-
oped a secondary infection and 50% of non-survivors had 
a secondary infection, although the type of infection was not 
specified [46]. In another study conducted among 85 fatal 
COVID-19 cases in Wuhan, almost 10% of patients had influ-
enza super-infection [47]. This highlights the importance of 
preventing secondary infection in persons infected with 
COVID-19. It has also been suggested that being protected 
against seasonal influenza makes the differential diagnosis of 
severe respiratory infections easier [43–45] and may reduce in 
general burden of viral respiratory diseases on national health-
care systems.
3.2. Pneumococcal vaccine
There are two types of pneumococcal vaccines: pneumococcal 
conjugate vaccine and pneumococcal polysaccharide vaccine 
[48]. Both types of vaccines contains pneumococcal capsular 
polysaccharide antigens that trigger an immune response, i.e. 
type-specific humoral antibodies; the main difference between 
the two vaccines is the number of polysaccharide types 
included and the presence or absence of conjugation: 13 in 
the conjugate vaccine, adsorbed onto an aluminum adjuvant 
and 23 in the non-conjugate vaccine [49]. These vaccines 
protect against pneumococcal disease, i.e. any type of illness 
caused by Streptococcus pneumoniae bacteria. These infections 
are associated with high mortality that can be prevented with 
pneumococcal vaccines [50].
A total of 13 studies were identified in MEDLINE, of which 
one original research article was found (Table 1). This observa-
tional study conducted in a cohort of 11,672 persons, of whom 
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818 persons had COVID-19, already described in section 3.1, 
found that persons who had been administered 
a pneumococcal vaccine in the same year as the study was 
conducted had a significantly lower risk of contracting COVID- 
19 [5]. There are currently no registered studies in clinicaltrials. 
gov or in the EU PAS Register which are investigating use, 
safety or effectiveness of the pneumococcal vaccine in the 
context of the COVID-19 pandemic.
Streptococcus pneumoniae is one of the major bacterial causes 
of community-acquired pneumonia (CAP) and can also be 
a cause of super-infection in CAP patients [51,52]. Indeed, the 
American Thoracic Society and Infectious Diseases Society of 
North America recommends that the treatment of adults with 
community-acquired pneumonia should be based on antibiotic 
activity against Streptococcus pneumoniae [53]. Pneumococcal 
vaccines reduces the number of hospitalizations for pneumonia 
in adults older than 65 years [54]. This is important because 
elderly persons with COVID-19 infection are at highest risk of 
mortality [55]. It is therefore likely that the pneumococcal vaccine 
could mitigate the impact of COVID-19 on healthcare systems, 
reducing morbidity and mortality due to non-COVID-19 respira-
tory infections, especially in those people who present important 
risk factors, such as advanced age and multi-morbidity [56]. It has 
been estimated that there are 10% of COVID-19 deaths are due 
to pneumococcal super-infection and are therefore preventable 
as they could have potentially be avoided by prior vaccination 
[42]. The negative impact of respiratory pneumococcal infection 
as a secondary infection along with viral infection is widely 
acknowledged [57]. Secondary infection occurred commonly in 
a small cohort of Chinese COVID-19 patients who died, but the 
pathogens were not described [46].
The WHO and the Australian region of New South Wales 
have categorically stated in their advice to the public that the 
pneumococcal vaccine does not protect specifically against 
COVID-19 infection [58,59]. We argue that the value of the 
pneumococcal vaccine in reducing the burden of excess 
deaths among persons with COVID-19 is likely to be signifi-
cant, as reported above [42].
3.3. BCG vaccine
The BCG vaccine is a live attenuated vaccine that has a protective 
effect against disseminated tuberculosis [60]. This vaccine trig-
gers a cell-mediated immune response which provides a variable 
degree of protection against Mycobacterium tuberculosis [61]. 
The duration of this immunity is unknown [61].
The BCG vaccine was found to improve immunogenicity to 
the H1N1 vaccine in healthy volunteers in a randomized, pla-
cebo-controlled study enrolling 40 persons [62]. Based on this 
and similar findings in other viral infections [63], it is thought that 
the BCG vaccine may improve immunity to SARS-CoV-2 suggest-
ing its potential role in preventing SARS-CoV-2 infection and/or 
reducing COVID-19 severity [64]. The BCG vaccine may activate 
trained innate immunity [4,16,65], leading to a massive release of 
interferon-gamma (IFN- γ), pro-inflammatory cytokines, includ-
ing various interleukin (IL) types (IL-1 β, IL-2, IL-6, IL-8, IL-10, IL-12, 
IL-17) and tumor necrosis factor (TNF), thus protecting against 
respiratory tract infections [6,16,65,66]. There is however limited 
clinical evidence to support the direct usefulness of this vaccine 
in COVID-19 infection and the available evidence is generally of 
low quality. A total of 60 published articles were identified in 
MEDLINE, of which four were considered to be of interest. These 
studies, which indirectly correlated morbidity and mortality 
among COVID-19 cases with compulsory tuberculosis vaccina-
tion program [6,15,29,67], are limited by some serious methodo-
logical flaws. Three of the studies showed that there is a strong 
relationship between BCG vaccine and the reduction of COVID- 
19 mortality/morbidity; however, they are not sufficient to estab-
lish the protective role of BCG vaccine with certainty because 
data are not linked at the patient level and the criteria to estab-
lish casual inference are therefore not available.
The ongoing seventeen trials of BCG as preventive strategy 
for COVID-19 pandemic will shed light on the role of this 
vaccine in the context of the current pandemic (Table 1). 
Most of these trials aim to recruit healthcare workers with 
the earliest results likely to be available by May 2021 
(NCT04417335). A total of 4 trials are in phase IV, while 12 
are in phase III and all of them except for one are randomized. 
The median size of the study populations is 1,200 (interquar-
tile range: 908–2,014). There are currently no registered obser-
vational studies in the EU PAS Register on BCG vaccine and 
COVID-19. The WHO does not recommend the use of the BCG 
vaccine to prevent COVID-19 specifically [68]. The ongoing 
clinical studies evaluating the benefit of the BCG vaccine in 
COVID-19 are presented in Table 2.
4. Development of SARS-CoV-2 vaccine: regulatory 
and clinical aspects
The high infection rate of the SARS-CoV-2, along with the high 
risk of negative outcomes among COVID-19 patients, has trig-
gered intense research activity to develop a specific vaccine 
against SARS-CoV-2 [69]. The concern triggered by the pan-
demic is so significant that the first COVID-19 vaccine candi-
date entered human clinical studies with unprecedented 
rapidity on 16 March 2020 [69,70], only three months after 
the virus was isolated by Chinese scientists [8].
There are several issues to consider in developing a reliable 
SARS-COV-2 vaccine candidate for mass manufacture and dis-
tribution. Firstly, it is still unclear what constitutes an optimal 
protective immune response against COVID-19. A study con-
ducted among 285 patients with COVID-19 showed that SARS- 
CoV-2 infection led to a robust immune response [71]. 
However, there is very limited evidence about what level 
and type of immunity is required to prevent re-infection. 
Secondly, there is a need for both clinical endpoints (i.e. 
hospitalization and disease severity, evaluated as high- 
intensity medical care) and immunological endpoints (i.e. ser-
oconversion) to assess the beneficial effects of a COVID-19 
vaccine. This requires either a large number of enrolees, 
encompassing the wide variety of clinical symptoms affecting 
COVID-19 patients [72], or a multi-trial strategy with smaller 
homogeneous samples and the involvement of laboratories 
having comparable validated serologic assays. This is impor-
tant to harmonize results among different vaccine products as 
well as among different vaccine trials. Thirdly, safety is 
a primary goal for vaccines that are given as preventive mea-
sure to healthy individuals, and there is also a risk that 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT REVIEW OF VACCINES 925
vaccination could make subsequent SARS-CoV-2 infection 
more severe [73]. There are in fact two different vaccine- 
mediated syndromes (i.e., antibody-dependent enhancement 
and vaccine-associated enhanced respiratory disease) which 
are likely to occur when the antibody response fails to effec-
tively neutralize the virus because of insufficient concentration 
or affinity or the wrong specificity [73].
With these aspects in mind, governmental authorities took 
important steps to help accelerating the development of pre-
vention and treatment options for COVID-19. For example, the 
U.S. National Institutes of Health (NIH), along with the Centers 
for Disease Control and Prevention (CDC), Food and Drug 
Administration (FDA) and the European Medicines Agency 
(EMA) are coordinating several biopharmaceutical companies 
in developing an international plan to promote a coordinated 
effort from research groups [74]. The planned Accelerating 
COVID-19 Therapeutic Interventions and Vaccines (ACTIV) 
partnership aims to build a collaborative platform to prioritize 
vaccine and drug candidates, streamline clinical trials, coordi-
nate regulatory processes and/or leverage assets between 
consortium members to accelerate the response to the 
COVID-19 pandemics.
4.1. Overview of COVID-19 candidate vaccines already 
in clinical development phase
Several institutions have developed and currently update 
the overview of the global landscape of COVID-19 vaccine 
development by mostly using publicly available sources 
[75]. Heterogeneity across vaccine candidates at the pre- 
clinical development phase has been documented, and 
the number of vaccines entering the clinical phase is sub-
stantial. Based on the WHO list, US clinicaltrials.gov and the 
Chinese Clinical Trial Registry, 27 clinical trials for 23 corre-
sponding vaccine candidates (4 RNA-based, 3 DNA-based, 5 
viral vector-based, 5 inactivated virus-based vaccines, 4 with 
protein subunits, and 2 with virus-like particles or cells) 
have been currently identified as recruiting patients by 
20 July 2020.
Table 3 shows the main characteristics of these trials: 
there are 11 phase I, 13 phase I/II, 2 phase II, and one 
phase II/III trials. However, the WHO website reports five 
phase III clinical trials: ISRCTN89951424, NCT04456595, 
ChiCTR2000034780, ChiCTR2000034780, NCT04470427 [76]. 
Among the reported trials, earliest results (i.e. by the end of 
December 2020) are expected for the following vaccines: 
BNT162 developed by BioNTech SE, an inactivated SARS- 
CoV-2 vaccine from Sinovac, and Gam-COVID-Vac Lyo from 
Gamaleya research. As far as phase II and III trials are con-
cerned the following vaccines are at the most advanced 
stage of development: Ad5-nCoV from CanSino Biologics 
(China) actually recruiting 508 study participants, mRNA- 
1273 from the US National Institute of Allergy and 
Infectious Diseases with 600 enrolled subjects, and the 
ChAdOx1 nCoV-19 which will enroll 10,260 persons. 
Overall, most of the trials are claiming to provide results 
by the end of 2021.
5. Post-marketing vaccine safety surveillance during 
the COVID-19 epidemic
Every approved vaccine carries a certain risk of adverse reac-
tions, just like every approved medication. Information on 
vaccine safety data is usually very limited in a pre-marketing 
setting, especially considering that the true risks and benefits 
of vaccines will play out in the long-term and in very large 
populations – often children or elderly, immunocompromized 
or otherwise vulnerable persons – as opposed to the small 
study population sizes and short observation periods in pre- 
marketing studies [77]. Nonetheless, in contrast to approved 
medications, which are generally used to treat a disease, vac-
cines are used to prevent disease in relatively healthy people. 
As a result, the threshold concerning acceptable vaccine risk is 
lower, in the sense that even a low risk may be considered 
unacceptable [78]. Moreover, potential adverse effects of vac-
cines are mainly immunologic, while adverse drug reactions 
are mostly dose- and mechanism-dependent effects, so more 
easily predictable [79]. Robust and proactive systems for vac-
cine post-marketing surveillance have been recently adopted 
to constantly monitor the quality, safety and efficacy of vac-
cines [80]. Several initiatives have been launched worldwide to 
perform post-authorization studies to rapidly investigate vac-
cine coverage, effectiveness, and safety throughout the vac-
cine life cycle using real-world data, such as healthcare claims 
data and electronic medical records. Nonetheless, vaccine 
post-marketing surveillance predominantly relies on sponta-
neous reporting systems (SRSs) [81].
Among the Good Pharmacovigilance Practices (GVP) drawn 
up by the EMA, there is a specific chapter concerning vaccines, 
aimed at strengthening and harmonizing the process of phar-
macovigilance for vaccines in EU countries [79]. This chapter 
focuses on vaccine-specific aspects and challenges that should 
be considered when planning routine and additional pharma-
covigilance activities for vaccines. Routine pharmacovigilance 
activities are based on the collection of Adverse Events 
Following Immunization (AEsFI) for the rapid monitoring of 
post-marketing vaccine safety. Besides routine or passive sur-
veillance, EMA requires vaccine manufacturers to plan addi-
tional pharmacovigilance activities in their ‘Risk minimization 
system’ which may be needed for special situations or pan-
demics, such as detecting strain replacement phenomena for 
vaccines that may protect against only some types of organ-
isms within a species. Other additional activities include asses-
sing the evidence of safety for novel vaccines or for vaccines 
with a novel adjuvant, assessing vaccine effectiveness, espe-
cially where pre-marketing data are limited, investigating clus-
ters of reported adverse events/reactions and finally, 
investigating whether there are higher than expected rates 
of vaccine failures and breakthrough infections in certain risk 
groups [82].
EudraVigilance is the system for collecting, managing and ana-
lyzing all Individual Case Safety Reports (ICSSs) related to adverse 
events to medicines or immunization authorized or being studied 
in clinical trials in the European Economic Area (EEA) [82]. ICSRs for 
AEsFI occurring after administration of the BCG vaccine, influenza 
vaccine, and pneumococcal vaccine collected in EudraVigilance 
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were extracted to investigate the impact of pandemic on vaccine 
surveillance. The number of ICSRs concerning the BCG, pneumo-
coccal and influenza vaccine were extracted during the pandemic 
COVID-19 period (1st January–9th  May 2020) and compared to the 
number of ICSRs during the corresponding quarter of 2019 (1st 
January–9th May 2019).
Compared to the January-May 2019 period, the number of 
ISCRs in the January–May 2020 period concerning the BCG 
vaccine was higher (N = 269 vs. 164). Reporting for the avail-
able pneumococcal vaccines was also slightly higher from 
January-May 2020 compared to January-May 2019 (N = 2,820 
vs. 2,470). The frequency of ICSRs for the seasonal influenza 
vaccine were practically identical during the COVID-19 pan-
demic compared to before (N = 595 vs. 548).
The comparison of ICSRs for the three vaccines in a period 
before and during the COVID-19 pandemic showed no differ-
ence in reporting, suggesting that vaccine safety monitoring 
has not been neglected because of changing health priorities. 
The COVID-19 pandemic will also likely impact the ICSRs of the 
SARS-CoV-2 vaccines themselves. After approval of a COVID-19 
vaccine, especially if through accelerated regulatory pathways, 
the detection of new potential safety signals should be as real- 
time as possible, to support regulatory decision-makers as the 
vaccine becomes more widely used. This is important as mass 
vaccination programs over a relatively short time period are 
expected. The quality of the rapidly generated vaccine safety 
data and the interpretation of this data will be critical.
6. Public health perspective on vaccination 
strategies to counteract COVID-19 pandemic
A recent paper on mortality data from 24 countries participating in 
the European mortality monitoring activity network, also known as 
EuroMOMO, estimated a notable all-cause excess mortality due to 
COVID-19 in people aged 65 years and older which accounted for 
over 90% of excess deaths [83]. The excess mortality greatly 
exceeded that observed in the past influenza seasons. Also, the 
report issued by the Italian National Institute of Statistics on the 
impact of COVID-19 pandemic on mortality in the first trimester of 
2020 has shown a significant increase in all-cause mortality as 
compared to the 2015–2019 period. The report has correlated this 
excess mortality, among other causes, with the indirect effects of 
the COVID-19 pandemic, namely the health system crisis [84]. 
Furthermore, besides being a potential primary cause of death, 
COVID-19 can also play a role as a worsening factor of underlying 
comorbidities that might possibly accelerate death. This is also true 
for influenza, which has an average excess mortality rate of 1.9–-
2.2 per 100,000 persons considering only influenza and pneumonia 
and 11.6–18.6 per 100,000 considering all causes [44]. Looking at 
the period from February 20th to 31st March 2020, the mortality rate 
in Italy has more than doubled in persons from 70 to 79 years of age 
as well as among those aged 80–89 [84]. Therefore, higher age is 
a risk factor for more severe disease. Similarly, the presence of 
comorbidities can increase the chance of infection and have 
a negative impact on infection outcome [85]. In fact, less than 4% 
of all patients who died in Italy from COVID-19 up to 14th May 2020 
were free of any comorbidity [86]. All these aspects highlight the 
importance of shifting to a life-long vaccination approach [87] as it 
is known that infectious diseases can result in a worse clinical 
outcome as well as worse impact on quality of life in elderly and 
among people with comorbidities [88]. It goes without saying that 
these two target groups will be a priority once a vaccine against 
COVID-19 is available. Nonetheless, in order to promote healthy 
aging and protect healthcare systems from potential work overload 
during the next influenza season and the potential concurrent new 
wave of COVID-19 infection, it is also important to encourage 
pneumococcal and influenza vaccination. Indeed Streptococcus 
pneumoniae was identified as one of the most common pathogens 
responsible for severe infections, or even death, during the three 
influenza pandemics of the 20th century and the first influenza 
pandemic of the 21th century [89]. In line with this evidence, pre-
ventive measures against S. pneumoniae should be considered in 
the preparation of influenza pandemic policies [89].
Preparedness and response plans are already used to tackle 
potential influenza pandemics worldwide. The COVID-19 pandemic 
reminds us of the importance of preparedness as to ensure the 
‘availability of capacities and capabilities to detect, notify, respond 
to and recover from an emergency’ [90]. The Italian National 
Pandemic Preparedness and Response Plan to an influenza pan-
demic addresses the importance of vaccination in all the pandemic 
phases [91]. In particular, during the interpandemic period, the 
organization of the seasonal influenza vaccination campaign 
makes it possible to lay the foundations for the collection of data 
during a pandemic period [91]. This aspect also highlights the 
importance of having the infrastructure, procedures and resources 
already available to deploy and administer a new vaccine in a short 
time to a large number of people. The planning of a vaccination 
campaign, such as that against influenza which recurs every year, 
includes decisions and instructions concerning the production, 
distribution, administration and monitoring of vaccines. The lack 
of existing national influenza vaccination programs has been 
shown to be an obstacle in the response to 2009 pandemic influ-
enza in the WHO Western Pacific Region, for instance [92]. This is 
not the case of the WHO European Region, but it should be kept in 
mind that coverage of target groups is still low even in Europe and 
this might undermine influenza and pandemic preparedness [93]. 
The proper functioning of a nationwide vaccination campaign is 
essential to guarantee that adequate infrastructures are available 
[94]. Other activities are also important, namely the training of 
people involved in the management of the pandemic and 
a suitable communication strategy. These two actions are of utmost 
importance for a widespread and successful vaccination campaign. 
The challenge behind optimizing the various public health inter-
ventions during a pandemic is highlighted by the fact that during 
the 2009 influenza pandemic, the coverage of the pandemic influ-
enza vaccine was as low as 4% of the target population, such as 
healthcare workers, blood donors, persons with at least one chronic 
condition and pregnant women [95]. In particular, an unambigu-
ous, reliable, thorough and transparent communication should be 
provided to all the stakeholders also in the light of improving trust 
in health authorities [96]. These actions are also required to increase 
confidence in vaccines and counteract the potential effects of 
a pandemic on vaccination coverage. It is interesting to see that 
in France a decline in influenza vaccine coverage was observed 
after the 2009 pandemic influenza, probably due to disputes on 
mass vaccination campaigns that led to a loss of trust in French 
health authorities [97]. The COVID-19 pandemic has already led to 
a decline in childhood vaccination coverage. In Michigan, for 
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example, there was a decline in vaccination coverage in all child-
hood milestone age cohorts and the number of doses administered 
in the first quarter of 2020 to children less than 2 years old was 
15.5% lower as compared to the previous two years [98]. Similarly, 
in England there was a decline in vaccination coverage as the 
number of first-dose measles-mumps-rubella vaccinations being 
19.8% lower in 2020 compared with 2019 [99]. These trends were 
likely due to the lockdown with resulting limitations in both the 
delivery of vaccines and the access to vaccination services by the 
population. A reduction in routine immunizations during the pan-
demic was also observed in developing countries. For example, in 
a rural area of South Africa, a 50% drop in child visits for immuniza-
tion has been observed immediately after the lockdown [100]. As 
a consequence, the return to normality may lead to possible out-
breaks of some vaccine-preventable diseases [101]. In fact, the 
disruption of health services due to the COVID-19 pandemic is 
clearly visible and its consequences should be carefully addressed 
in as soon as possible.
The judicious and rational planning of future vaccination 
campaigns against influenza and COVID-19 is required now 
more than ever as there is also evidence suggesting that the 
increase in influenza vaccination coverage could help to con-
tain the spread of COVID-19 [102]. Similarly, a timely and 
efficient uptake of routine vaccinations, including that against 
Streptococcus pneumoniae in high risk groups, should be 
a priority. Eventually, the regular collection of data on the 
efficacy and safety of SARS-CoV-2 vaccines will be essential 
for both the decision-making process as well as for the addi-
tional and continuous systematic data collection on the role of 
influenza and Streptococcus pneumoniae co-infections and vac-
cinations against them on COVID-19 outcomes.
7. Conclusions
There are immunologic mechanisms by which existing vaccines, 
such as the BCG vaccine, the pneumococcal vaccine and the 
influenza vaccine, may hypothetically directly prevent COVID-19 
prevention. However, the major contribution of these vaccines, in 
particular pneumococcal and influenza vaccines, probably mainly 
remains that of preventing specific respiratory diseases co- 
occurring with COVID-19 and leading to worse prognoses, thus 
also reducing the burden on national healthcare systems. An 
additional contribution of these vaccines is likely to be that of 
aiding the differential diagnosis of COVID-19. As such, vaccination 
campaigns concerning existing vaccines addressing frailer popu-
lation should be implemented. On the other hand, there are 
several specific SARS-CoV-2 vaccine candidates in the pipeline 
which have entered the clinical development phase at an unpre-
cedented rate. Past experience has shown that for the pandemic 
vaccine to have a high uptake level, concerted public health 
interventions and communication strategies will be needed.
8. Expert opinion
The pressure to identify drugs or vaccines that can be rapidly used 
in the COVID-19 pandemic has led to the hypothesis that three 
existing vaccines may be beneficial, namely the BCG vaccine, the 
pneumococcal vaccine and the influenza vaccine. All three vac-
cines are widely considered to be effective and safe to prevent the 
diseases they were originally intended to prevent tuberculosis, 
thereby improving public health considerably. There is limited 
evidence of a direct benefit of these vaccines specifically on the 
prevention of COVID-19 although there are plausible immunologic 
mechanisms by which these vaccines may improve the immune 
response to SARS-CoV-2. The hypothesis that they may also pre-
vent COVID-19 arises from a series of observations, which allow us 
to envision the mechanisms of action through which this putative 
protection might occur, namely antigen mimicry, by-stander acti-
vation and trained immunity. In this context, it appears reasonable 
to distinguish between live/attenuated vaccine and inactivated 
or second/third generation vaccines, the latter including prepara-
tion by genetic engineering which contain subsections as protein 
forms or recombinant vector vaccines. Live/attenuated vaccine, 
such as BCG, are clearly more likely to result in putative trained 
immunity, which hardly can be envisaged by administration of 
non-live/attenuated viral proteins contained in influenza vaccines 
or bacteria polysaccharides of pneumococcal vaccines. Similarly 
influenza vaccines, which are mainly composed of viral sub- 
particles, are unlikely to result in a trained innate immunity, 
although a nasal spray of live attenuated influenza vaccine (LAIV, 
Q/LAIV), which contains the live but attenuated form of the virus, is 
also currently available in Europe [37] and America [103] may 
potentially lead to trained innate immunity. There is no informa-
tion currently available regarding the possible interference of the 
influenza LAIV/QLAIV with other diseases. Finally, it is worth noting 
that the role of the distinct adjuvants of above-mentioned vaccines 
in both by-stander and trained immunity mechanisms of vaccine 
interference remains to be elucidated. In addition to these strictly 
immunological mechanisms, as we reported above, it has been 
recently observed that influenza virus can induce the in vitro 
upregulation of mRNA for ACE2, the main human cell receptor 
for SARS-CoV-2. Interestingly, the increase of ACE2 mRNA in the 
presence of the influenza virus occurred in alveolar epithelial cells, 
but not in macrophages [41]. It remains to be elucidated whether 
this increased expression of ACE2 correlates with a higher risk of 
either SARSR-CoV-2 infection or COVID-19 severity.
Based on the number of ongoing experimental studies 
identified, the BCG vaccine seems to have been by far the 
most commonly investigated vaccine in the context of COVID- 
19. However, the safety of administering an additional vacci-
nation during the early phases of a challenging infection, such 
as COVID-19, should carefully be weighed against the 
expected benefit. The timing and sequence of vaccine admin-
istration might even be detrimental to an effective immune 
response against the invading SARS-CoV-2 pathogen.
However, the main role of the vaccines in question is 
likely to concern the prevention of respiratory super-infec-
tions which can potentially increase the risk of morbidity 
and mortality in persons affected with COVID-19. Indeed, 
super-infections have been commonly reported among 
persons affected with COVID-19 [46,47,104,105,106,107]. 
Studies comparing the overall reduction in morbidity/mor-
tality among COVID-19 patients who have received routine 
influenza, BCG and pneumococcal vaccines are likely to be 
a useful addition to what is known about these vaccines, as 
there is currently no published epidemiological large-scale 
study [42]. In this case, the comparison group might con-
sist of persons affected with COVID-19 who were eligible 
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for the BCG, influenza and pneumococcal vaccine (i.e. not 
having any medical contraindications) but elected not to 
take this vaccination. The main study group might be 
persons with COVID-19 who took their routine vaccines 
as indicated. The secondary use of previously collected 
data is ideal to address the question of whether routine 
vaccinations reduce the morbidity and mortality among 
COVID-19 infected patients. There are several databases 
which could be used to conduct such a study. For example, 
Italian regional claims databases contain information on 
vaccinations along with a very good temporal and geo-
graphic coverage [108]. There are also electronic medical 
record database, such as The Health Improvement Network 
database in the UK, also known as THIN [109], the 
Integrated Primary Care Information database in the 
Netherlands, also known as IPCI [110] and Base de datos 
para la Investigación Farmacoepidemiológica en Atención 
Primaria in Spain, also known as BIFAP [111], which also 
have information on vaccinations and good temporal and 
geographic coverage. Electronic healthcare data from dif-
ferent countries has also been used to conduct multi- 
country studies on vaccine use [112,113]. Such databases 
have immense potential, particularly in the context of 
a pandemic because they can leverage data which has 
already been collected. As a result, studies can be con-
ducted very rapidly.
The race to develop a vaccine specific to SARS-CoV-2 
has led to several potential vaccine candidates which are 
expected to be launched in the coming months. The global 
scale of the pandemic has brought together several inter-
national regulatory and scientific bodies to produce and 
share key safety and efficacy data for the novel vaccines in 
parallel. Such international collaboration will certainly 
accelerate the marketing and distribution of vaccines 
against COVID-19. Even here, observational studies have 
a lot of potential, particularly in vaccine safety monitoring 
once the vaccine is launched. The public perception of 
vaccine safety is of great importance because it may limit 
vaccine uptake. The value of having high-quality transpar-
ent research in countering public distrust while providing 
high-quality evidence was implicitly recognized in the 
Accelerated development of vaccine benefit-risk collabora-
tion in Europe (ADVANCE) project, funded by the 
Innovative Medicines Initiative and conducted in colla-
boration between the European Centre for Disease 
Prevention and Control and the European Medicines 
Agency, and national public health and regulatory bodies, 
vaccine manufacturers, and academic centers [114]. 
Accordingly, EMA has commissioned a large independent 
study for the rapid and accurate monitoring of the SARS- 
CoV-2 vaccine safety as soon as this is marketed [115].
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Appendix Box 1: Search queries applied to MEDLINE 
on 22 July 2020
Vaccine Search query applied to MEDLINE
Influenza 
vaccine
COVID-19 OR SARS-CoV-2 OR severe acute respiratory 
syndrome coronavirus 2 OR coronavirus di Wuhan OR 
coronavirus OR MERS-CoV OR middle east respiratory 
syndrome coronavirus 
AND 
influenza vaccine OR influenza vaccination OR flu shots 
OR flu vaccine OR flu vaccination OR flu jabs
Pneumococcal 
vaccine
COVID-19 OR SARS-CoV-2 OR severe acute respiratory 
syndrome coronavirus 2 OR coronavirus di Wuhan OR 
coronavirus OR MERS-CoV OR middle east respiratory 
syndrome coronavirus 
AND 
pneumococcal vaccine OR pneumococcal vaccination OR 
PCV OR pneumococcal conjugate vaccine OR PPSV OR 
pneumococcal polysaccharide vaccine
BCG vaccine COVID-19 OR SARS-CoV-2 OR severe acute respiratory 
syndrome coronavirus 2 OR coronavirus di Wuhan OR 
coronavirus OR MERS-CoV OR middle east respiratory 
syndrome coronavirus 
AND 
BCG vaccine OR Bacillus Calmette–Guérin vaccine OR TB 
vaccine OR tuberculosis vaccine
Abbreviations: BCG: Bacillus Calmette–Guérin 
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